Venus Concept Stock News

TORONTO, April 04, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quart

Venus Concept Inc. (VERO) CEO Dom Serafino on Q4 2021 Results - Earnings Call Transcript

Venus Concept (VERO) delivered earnings and revenue surprises of 33.33% and 0.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that managemen

TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quart

Venus Concept (VERO) has won FDA 510(k) clearance to market its Venus BlissMAX device in the U.S.BlissMAX is a medical aesthetic platform that serves as a comprehensive solution for

Venus Concept (VERO) filed with U.S. SEC to offer 13.6M shares including 9.8M shares and 3.8M shares issuable on conversion of outstanding shares of nonvoting convertible

Venus Concept <> shares have surged after the company issued preliminary revenue results for Q4 and FY21.For the three months ended December 31, 2021, prelim total GAAP revenue

Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati

TORONTO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has completed a non-brokered private placement (the Private Placement) of common shares of the Company (the Shares) and preferred nonvoting shares (Preferred Nonvoting Shares). Pursuant to the Private Placement, an aggregate of 9,808,418 Shares and 3,790,755 Preferred Nonvoting Shares were issued at a price of US$1.25 per share, for aggregate gross proceeds to the Company of approximately $17 million. The preferred nonvoting shares are convertible on a one-for-one basis into Shares upon receipt of conversion notice by the Company from the holder. The financing was led by a new investor - Masters Special Situations, LLC and affiliates thereof (Masters). Existing investors, EW Healthcare Partners and HealthQuest Capital, and independent director, Keith Sullivan, also participated in the financing. The gross proceeds to the Company from the Private Placement are expected to be $17 million, before offering expenses, which will be used for working capital, general corporate purposes and funding the development of AIme, the Companys next generation robotic technology platform for medical aesthetic applications.

Key Prominent Players Covered in the Laser Hair Removal Market Research Report Are CANDELA CORPORATION (Massachusetts U.S) , Lynton Lasers Ltd (U.K.) , Alma Lasers (Israel) , Fotona (Texas U.S) , Venus Concept (Toronto Canada) , Venn Healthcare (U.K.) , Sciton Inc. (California, U.S) , Lumenis Ltd. (Israel) , Cynosure (Massachusetts U.S) , Cutera (California, U.S) Key Prominent Players Covered in the Laser Hair Removal Market Research Report Are CANDELA CORPORATION (Massachusetts U.S) , Lynton Lasers Ltd (U.K.) , Alma Lasers (Israel) , Fotona (Texas U.S) , Venus Concept (Toronto Canada) , Venn Healthcare (U.K.) , Sciton Inc. (California, U.S) , Lumenis Ltd. (Israel) , Cynosure (Massachusetts U.S) , Cutera (California, U.S)

Beauty Health (NASDAQ:SKIN) and Venus Concept (NASDAQ:VERO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Institutional & Insider Ownership 92.9% of Beauty Health shares are owned by institutional investors. Comparatively, 41.3% []

Treace Medical Concepts (NASDAQ:TMCI) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Analyst Ratings This is a breakdown of current ratings and price targets for Treace []

The global Skin Tightening Treatment market is expected to witness promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer

Venus Concept (NASDAQ:VERO) had its price target trimmed by Stifel Nicolaus from $2.50 to $2.00 in a research note issued to investors on Friday, The Fly reports. The firm currently has a hold rating on the stock. Separately, Zacks Investment Research downgraded shares of Venus Concept from a buy rating to a hold rating in []